X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (927) 927
niacinamide - analogs & derivatives (723) 723
phenylurea compounds (722) 722
index medicus (632) 632
male (599) 599
benzenesulfonates - administration & dosage (595) 595
female (496) 496
animals (436) 436
pyridines - administration & dosage (435) 435
oncology (406) 406
benzenesulfonates - therapeutic use (372) 372
sorafenib (364) 364
middle aged (340) 340
pyridines - therapeutic use (282) 282
aged (281) 281
cancer (258) 258
benzenesulfonates - adverse effects (251) 251
benzenesulfonates - pharmacology (249) 249
treatment outcome (246) 246
adult (239) 239
pyridines - adverse effects (217) 217
kidney neoplasms - drug therapy (211) 211
antineoplastic agents - therapeutic use (202) 202
carcinoma, renal cell - drug therapy (201) 201
mice (185) 185
antineoplastic combined chemotherapy protocols - therapeutic use (183) 183
antineoplastic agents - administration & dosage (182) 182
rats (166) 166
liver neoplasms - drug therapy (152) 152
carcinoma, hepatocellular - drug therapy (147) 147
pharmacology & pharmacy (146) 146
care and treatment (136) 136
antineoplastic agents - adverse effects (128) 128
bevacizumab (124) 124
protein kinase inhibitors - therapeutic use (122) 122
pyridines - pharmacology (122) 122
cell line, tumor (119) 119
research (117) 117
protein kinase inhibitors - administration & dosage (111) 111
sunitinib (110) 110
kidney neoplasms - pathology (108) 108
dose-response relationship, drug (107) 107
aged, 80 and over (104) 104
endothelial growth-factor (101) 101
indoles - administration & dosage (96) 96
administration, oral (94) 94
angiogenesis (93) 93
benzenesulfonates - pharmacokinetics (91) 91
drug administration schedule (91) 91
therapy (91) 91
time factors (90) 90
pyrroles - administration & dosage (85) 85
antitumor-activity (84) 84
drug therapy (84) 84
renal cell carcinoma (84) 84
chemotherapy (83) 83
hepatocellular carcinoma (83) 83
antibodies, monoclonal, humanized (81) 81
antineoplastic agents (80) 80
article (79) 79
protein kinase inhibitors - adverse effects (79) 79
renal-cell carcinoma (79) 79
antineoplastic combined chemotherapy protocols - adverse effects (78) 78
prognosis (77) 77
antimitotic agents (75) 75
expression (75) 75
indoles - therapeutic use (75) 75
neoplasms - drug therapy (75) 75
disease-free survival (74) 74
pyrroles - therapeutic use (74) 74
benzenesulfonates (73) 73
apoptosis (72) 72
disease models, animal (72) 72
rats, sprague-dawley (71) 71
antineoplastic agents - pharmacology (69) 69
interferon-alpha (69) 69
survival (68) 68
carcinoma, renal cell (67) 67
mice, nude (66) 66
carcinoma, hepatocellular - pathology (65) 65
liver neoplasms - pathology (65) 65
carcinoma, renal cell - secondary (64) 64
metastasis (64) 64
neoplasm staging (64) 64
clinical trials as topic (63) 63
medicine & public health (62) 62
carcinoma, renal cell - pathology (61) 61
retrospective studies (61) 61
survival rate (60) 60
sirolimus - analogs & derivatives (59) 59
liver cancer (58) 58
vascular endothelial growth factor (58) 58
carcinoma (57) 57
pharmacokinetics (57) 57
xenograft model antitumor assays (57) 57
cell proliferation - drug effects (56) 56
drug synergism (56) 56
indoles - adverse effects (56) 56
tumors (56) 56
raf kinase (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1133) 1133
German (24) 24
Russian (18) 18
French (13) 13
Japanese (11) 11
Chinese (8) 8
Spanish (7) 7
Italian (4) 4
Hungarian (3) 3
Czech (1) 1
Dutch (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 32, pp. 4017 - 4025
Therapeutic drug monitoring (TDM) provides valuable guidance for dose adjustment of antibiotics, immunosuppressives, antiepileptics, and other drugs, but its... 
ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | FC-GAMMA-RIIIA | PROGRESSION-FREE SURVIVAL | MULTICENTER PHASE-II | SQUAMOUS-CELL CARCINOMA | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | SUNITINIB MALATE SU11248 | CHRONIC MYELOID-LEUKEMIA | IMATINIB PLASMA-LEVELS | Neoplasms - metabolism | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Thiazoles - blood | Injections, Intravenous | Area Under Curve | Pyrimidines - blood | Humans | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Half-Life | Thiazoles - administration & dosage | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Drug Monitoring - methods | Indoles - administration & dosage | Antibodies, Monoclonal - blood | Antibodies, Monoclonal, Humanized | Neoplasms - blood | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Cetuximab | Piperazines - blood | Everolimus | Molecular Targeted Therapy - methods | Dasatinib | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Indoles - blood | Rituximab | Pyrroles - blood | Sirolimus - blood | Evidence-Based Medicine | Imatinib Mesylate | Neoplasms - drug therapy | Sirolimus - administration & dosage | Antibodies, Monoclonal, Murine-Derived - blood | Pyridines - blood | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - blood | Benzamides
Journal Article
Journal Article
Cancer Letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Abstract Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics. Multi-cytotoxic drug regimens have been highly successful,... 
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | ACTIVATION | SRC | BCR-ABL | TUMOR | MECHANISMS | SIMULATION | CHEMOTHERAPY | ONCOLOGY | RESISTANCE | SYSTEMS | KINASES | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Cell culture | Values | Cell division | Cytotoxicity | Regression analysis | Kinases | Cancer therapies | Cell growth | Cell cycle | Software | Mutation | Drug dosages | Methods | Tumors | Apoptosis | Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 10/2008, Volume 13, Issue 10, pp. 1084 - 1096
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2006, Volume 24, Issue 26, pp. 4293 - 4300
Purpose This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity,... 
BAY-43-9006 | HEPATITIS-C VIRUS | TUMOR PROGRESSION | ONCOLOGY | KINASE | DOXORUBICIN | GENE-EXPRESSION | RESISTANCE | COMBINATION CHEMOTHERAPY | RAF/MEK/ERK PATHWAY | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Predictive Value of Tests | Extracellular Signal-Regulated MAP Kinases - blood | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | RNA, Neoplasm - blood | Benzenesulfonates - adverse effects | Liver Neoplasms - blood | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Carcinoma, Hepatocellular - genetics | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Carcinoma, Hepatocellular - blood | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Treatment Outcome | Biomarkers, Tumor - blood | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Neoplasm Staging
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 11/2009, Volume 161, Issue 5, pp. 1045 - 1051
Summary Background  The multitargeted kinase inhibitors sorafenib and sunitinib have improved treatment of solid tumours including renal cell carcinoma and... 
sunitinib | sorafenib | cutaneous adverse effects | Cutaneous adverse effects | Sunitinib | Sorafenib | THERAPY | HAIR | MANAGEMENT | KIT | IMATINIB | HAND-FOOT | FOOT SKIN REACTION | DERMATOLOGY | Niacinamide - analogs & derivatives | Humans | Middle Aged | Hand Dermatoses - chemically induced | Male | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Skin Diseases - pathology | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Young Adult | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Adult | Female | Retrospective Studies | Carcinoma, Renal Cell - drug therapy | Drug Eruptions - etiology | Skin Diseases - chemically induced | Pyridines - administration & dosage | Administration, Oral | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Stomatitis - chemically induced | Foot Dermatoses - chemically induced | Alopecia - chemically induced | Aged | Kidney Neoplasms - drug therapy | Antimitotic agents | Complications and side effects | Liver cancer | Medical colleges | Care and treatment | Antineoplastic agents | Tumors | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 13, pp. 1484 - 1491
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2008, Volume 26, Issue 22, pp. 3709 - 3714
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2011, Volume 29, Issue 24, pp. 3293 - 3300
Journal Article
European Urology, ISSN 0302-2838, 2007, Volume 53, Issue 5, pp. 917 - 930
Abstract Objective To provide a systematic review of the side effects associated with sorafenib, sunitinib, and temsirolimus and to provide an outline of... 
Urology | Temsirolimus | Side effects | Sunitinib | Sorafenib | sunitinib | MAMMALIAN TARGET | BAY-43-9006 | sorafenib | DAYS ON/7 DAYS | RAF KINASE | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | INTERFERON-ALPHA | temsirolimus | PHARMACOKINETICS | UROLOGY & NEPHROLOGY | side effects | REFRACTORY SOLID TUMORS | PHASE-I | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor | Drug-Related Side Effects and Adverse Reactions - prevention & control | Prognosis | Humans | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Indoles - administration & dosage | Benzenesulfonates - adverse effects | Dose-Response Relationship, Drug | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Carcinoma, Renal Cell - drug therapy | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Pyridines - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Sirolimus - administration & dosage | Indoles - adverse effects | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Drug-Related Side Effects and Adverse Reactions - diagnosis | Metastasis | Life Sciences | Pharmaceutical sciences | Cancer
Journal Article
Radiology, ISSN 0033-8419, 2012, Volume 263, Issue 2, pp. 590 - 599
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 09/2012, Volume 97, Issue 9, pp. 3046 - 3050
Journal Article
Cancer Research, ISSN 0008-5472, 05/2009, Volume 69, Issue 9, pp. 3927 - 3936
Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive... 
BAY-43-9006 | ONCOLOGY | MCL-1 | BCR-ABL | IMATINIB | GROWTH | DOWN-REGULATION | MYELOGENOUS LEUKEMIA | RECEPTOR | MULTIKINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Niacinamide - analogs & derivatives | Piperazines - administration & dosage | Apoptosis - drug effects | Humans | Pyrazines - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Fusion Proteins, bcr-abl - biosynthesis | Interleukin-3 - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Benzenesulfonates - pharmacology | Caspases - metabolism | Acetophenones - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Boronic Acids - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Protein-Tyrosine Kinases - biosynthesis | Bortezomib | Pyridines - administration & dosage | Nitrophenols - administration & dosage | Mitochondria - drug effects | Pyrimidines - pharmacology | Enzyme Activation - drug effects | Imatinib Mesylate | Piperazines - pharmacology | Drug Synergism | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Protein Kinase Inhibitors - administration & dosage | Benzopyrans - administration & dosage | Fusion Proteins, bcr-abl - genetics | Biphenyl Compounds - administration & dosage | Fusion Proteins, bcr-abl - antagonists & inhibitors | K562 Cells | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Apoptosis - physiology | Benzamides | Mutation | Mitochondria - physiology | Sulfonamides - administration & dosage | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article